Sagimet reports Q3 2025 net loss $12.9M; advances denifanstat + resmetirom combo trial

Sagimet Biosciences Inc.

2025-Q3 EPS reported -$1.28 vs consensus -$0.39 ▼ miss (-225.5%)

Net loss for Q3 2025 was $12.9M vs $14.6M YoY; nine-month net loss $41.5M vs $29.4M.
Cash, cash equivalents and marketable securities totaled $125.5M as of Sept 30, 2025.
Phase 1 PK trial of denifanstat plus resmetirom in MASH cirrhosis underway; data expected 1H 2026.
Partner Ascletis completed pre-NDA consultation with China NMPA for denifanstat in acne vulgaris; NDA submission planned.
Marie O'Farrell promoted to CSO and Liz Rozek to Chief Legal & Admin Officer effective Nov 1, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.